What is the main purpose of this Amgen 8-K filing?

The primary purpose of this Form 8-K filing is to disclose updated information regarding recent developments, risk factors, and legal proceedings to the public, in compliance with Regulation FD. This ensures that all investors have access to the same material information.

Where can I find the specific updated information mentioned in the filing?

The specific updated information is located in three separate exhibits attached to the Form 8-K: Exhibit 99.1 (Recent Developments), Exhibit 99.2 (Risk Factors), and Exhibit 99.3 (Legal Proceedings). These exhibits are incorporated by reference into the filing.

What should investors be aware of regarding the 'forward-looking statements' in this report?

Investors should understand that forward-looking statements are based on current expectations and involve risks and uncertainties. Amgen explicitly states that actual results could differ materially from those projected in these statements. It is advisable to carefully review the 'Risk Factors' section for a detailed understanding of potential risks.

Does Amgen plan to update this information regularly?

The filing notes that Amgen does not have an obligation to publicly update these forward-looking statements unless required by federal securities laws. Investors should monitor future SEC filings for any subsequent updates.

AMGN 8-K: Regulation FD

Summary

Amgen Inc. (AMGN) filed a Form 8-K on May 22, 2007, to disclose updated information concerning recent developments, risk factors, and legal proceedings, as required by Regulation FD. This filing is intended to provide investors with current insights into material information affecting the company. Investors should review the attached exhibits (99.1, 99.2, and 99.3) for a comprehensive understanding of these updates. The report emphasizes that forward-looking statements, which are common in such disclosures, are based on current expectations and involve inherent risks and uncertainties. Amgen explicitly states that actual outcomes could differ materially from these projections. The filing serves as a mechanism to disseminate important, potentially material information to the public in a fair and timely manner.

Key Highlights

1Amgen filed a Form 8-K on May 22, 2007, to comply with Regulation FD disclosure requirements.
2The filing disseminates updated information regarding 'Recent Developments,' 'Risk Factors,' and 'Legal Proceedings' as of May 21, 2007.
3Investors are directed to three specific exhibits (99.1, 99.2, 99.3) for detailed information on these updates.
4The report contains standard cautionary language regarding forward-looking statements, highlighting that actual results may differ from expectations.
5This filing ensures that material updates are publicly disclosed, providing a basis for investor decision-making.
6The company is not obligated to update forward-looking statements unless required by law.

AMGEN INC 8-K Report, Regulation FD Disclosure (May 22, 2007)

Summary

Key Highlights

Frequently Asked Questions